Neumora Invest Advisor

Neumora Therapeutics Hosts Roundtable on Potential of Navacaprant for Neuropsychiatric Disorders Aug 15, 2024

Neumora Therapeutics Embarks on Phase 1 Clinical Study for NMRA-266, Targeting Schizophrenia Treatment Nov 27, 2023